Hamilton, Ontario, Canada, December, 2024 – AtomVie Global Radiopharma (AtomVie), a global leader in radiopharmaceutical contract development and manufacturing (CDMO), has appointed Dr. Pratibhash (Bosh) Chattopadhyay as Chief Business Officer (CBO). Dr. Chattopadhyay brings over 25 years of expertise in life sciences, with a strong track record of advancing commercialization efforts in oncology and pharmaceutical sectors. His career has included leadership roles at BASF, Catalent, and Matica Biotechnology, where he specialized in contract development, advanced drug delivery, and formulation technologies.
Dr. Chattopadhyay holds a Doctorate in Chemical Engineering from Auburn University and an MBA from Duke University’s Fuqua School of Business, and is widely recognized for his strategic acumen and innovative contributions to the pharmaceutical industry.
Joining AtomVie during a pivotal expansion phase, Dr. Chattopadhyay will lead efforts to advance AtomVie’s strategic growth initiatives as the company prepares to launch its state-of-the-art, 72,300-square-foot facility in 2025. The new facility will increase production capacity over tenfold, enabling AtomVie to meet the rising global demand for radiopharmaceuticals.
“I am thrilled to join AtomVie at such an exciting time in its growth,” said Dr. Pratibhash Chattopadhyay, Chief Business Officer. “The company’s commitment to enhancing radiopharmaceutical manufacturing capacity and delivering innovative therapeutic solutions reflects its dedication to transforming patient care. I look forward to collaborating with the talented AtomVie team and global partners to provide impactful treatments that address unmet medical needs and improve patients’ quality of life.”
Bruno Paquin, CEO of AtomVie, added, “Dr. Chattopadhyay’s deep knowledge of the pharmaceutical industry and proven ability to lead commercial strategy and innovation make him an invaluable addition to our leadership team. His expertise will be instrumental in expanding our partnerships and fulfilling the growing global need for radiopharmaceuticals. We are excited to welcome him to AtomVie and look forward to his contributions to our success in the CDMO industry.”
With its unmatched capabilities, AtomVie is poised to lead the development, manufacturing, and distribution of high-quality radiopharmaceuticals to global markets. The company’s focus on innovation and operational excellence ensures it remains at the forefront of delivering advanced therapeutic solutions that transform lives.
About AtomVie Global Radiopharma Inc. (AtomVie):
AtomVie is a global leader in radiopharmaceutical CDMO services, specializing in GMP manufacturing and worldwide distribution of clinical and commercial radiopharmaceuticals. AtomVie provides end-to-end support, including scientific, regulatory, quality, logistics, and business expertise. Serving clients in over 25 countries, AtomVie is committed to advancing radiopharmaceutical development from clinical studies to commercialization. Its cutting-edge 72,300-square-foot facility in Hamilton, Ontario, is set to launch in 2025, cementing its position as a trusted partner in delivering innovative solutions to address global healthcare challenges.
Click Here to Join HR TODAY WhatsApp Channel
Read Also : People Analytics Teams Still Struggle to Deliver Business Impact, Warns The Josh Bersin Company
